Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) stock is trading lower on Thursday. The company released patient updates on ...
Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a ...
A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for ...
Short-course induction chemotherapy prior to chemoradiotherapy should be considered a standard of care, according to ...
Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...
For a subset of patients with inoperable or metastatic HR-positive/HER2-negative breast cancer, treatment with datopotamab ...
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent GlioblastomaCohort A Data ...
Patients with limited-stage SCLC were randomly assigned to receive durvalumab with or without tremelimumab or placebo as ...
A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and ...
Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback